| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT04056741 Details | 2023-11-01 Interventional | 2 | - | Pulmonary Surfa… Lung Diseases Chronic Lung Di… RDS of Prematur… Surfactant Prot… | alteration of study required - | |||
| NCT02403323 2014-003855-76 Details | 2023-11-01 Interventional | 3 | - | Etrolizumab Crohn Disease | The study was terminated due to program discontinuation, based on mixed efficacy results in the
parent studies. There were no safety concerns. - | |||
| NCT02118584 2013-004435-72 Details | 2023-11-01 Interventional | 3 | 1822 | Etrolizumab Colitis Colitis, Ulcera… Ulcer Ulcerative Coli… | The study was terminated due to program discontinuation, based on mixed efficacy results in the
parent studies. There were no safety concerns. - | |||
| NCT04770155 Details | 2023-10-31 Interventional | 1 | 8 | Bosentan Sildenafil Citr… Racial Disparit… Vascular Functi… | Despite significant effort, we were unable to obtain the supply of drugs and supplements needed
for the various arms of this Clinical Trial. The only data collected were baseline measurements and no participants were ever given either intervention; the investigator was never able to obtain the treatments to use for the planned intervention arm of the study, resulting in its termination. | |||
| NCT04751955 Details | 2023-10-31 Interventional | 1/2 | 0 | Capecitabine Colorectal Neop… Colorectal Canc… | This clinical trial was not finally approved by the Korea FDA. - | |||
| NCT04601324 Details | 2023-10-31 Interventional | 4 | 0 | Azelastine Fluticasone Xhance Rhinitis Rhinitis, Aller… Allergic Rhinit… | PI did not pursue this study - | |||
| NCT05525455 Details | 2023-10-30 Interventional | 1/2 | 9 | Immune Checkpoi… Neoplasms Advanced Cancer Advanced Solid … Cancer Oncology | Company operational decision. Decision to stop study is not due to safety or efficacy concerns. - | |||
| NCT05151471 Details | 2023-10-30 Interventional | 3 | 202 | Edaravone ALS | Futility Analysis of parent study MT-1186-A02 was met. - | |||
| NCT04983407 Details | 2023-10-30 Interventional | 1/2 | 34 | Gemcitabine Paclitaxel Adenocarcinoma Pancreatic Aden… | Due to business reasons - | |||
| NCT04300140 Details | 2023-10-30 Interventional | 1/2 | 72 | Nivolumab Carcinoma Carcinoma, Rena… Clear Cell Rena… | Due to business reasons - | |||
| NCT04212650 Details | 2023-10-30 Interventional | 1/2 | 1 | Losartan Fibrosis Osteoarthritis,… Cartilage Damag… Hip Impingement… Hip Osteoarthri… | redesigned trial using another placebo controlled drug Per opinion of the Principal Investigator, Losartan is now clinically indicated as a standard of care post-operative therapy for patients undergoing hip microfracture surgeries. The study was terminated early, resulting in a singular subject enrolled for data analysis. The subject elected to withdraw from the study prior to the first follow-up data collection timepoint. | |||
| NCT03992196 Details | 2023-10-30 Interventional | 3 | 10 | Rotigotine Psychomotor Agi… Restless Legs S… Syndrome | Sponsor decision; Not a safety decision - | |||
| NCT03970200 Details | 2023-10-30 Interventional | 2 | 15 | Anti-Bacterial … Clostridium Inf… Communicable Di… Infections Severe Clostrid… Severe-Complica… | Administrative reasons. - | |||
| NCT02470585 2014-005070-11 Details | 2023-10-30 Interventional | 3 | 1140 | Carboplatin Paclitaxel Veliparib Ovarian Neoplas… Ovarian Cancer Ovarian Neoplas… | Business decision not related to patient safety - | |||
| NCT01545141 Details | 2023-10-27 Interventional | 1/2 | 15 | Celecoxib Interferon alph… Interferon-alfa… Interferon-alph… Interferons Poly I-C poly(I).poly(c1… Colorectal Neop… Colorectal Canc… Colorectal Carc… Colorectal Tumo… Neoplasms, Colo… | - - | |||
| NCT05329545 Details | 2023-10-26 Interventional | 3 | 20 | Immunoconjugate… Carcinoma, Ovar… Fallopian Tube … Hypersensitivit… Ovarian Neoplas… Fallopian Tube … High Grade Sero… Primary Periton… | Study Terminated by Sponsor - | |||
| NCT04320940 Details | 2023-10-26 Interventional | 3 | 4 | Phenobarbital Epilepsy, Benig… Seizures | Insufficient participant recruitment hindered the study's progress, preventing robust data
collection and compromising statistical power - | |||
| NCT04245722 Details | 2023-10-26 Interventional | 1 | 98 | Bendamustine Hy… Cyclophosphamid… Fludarabine Obinutuzumab Rituximab Leukemia Leukemia, Lymph… Leukemia, Lymph… Lymphoma Lymphoma, B-Cel… Chronic Lymphoc… | The study was terminated by the Sponsor. - | |||
| NCT04023071 Details | 2023-10-26 Interventional | 1 | 72 | Bendamustine Hy… Cyclophosphamid… Fludarabine Obinutuzumab Rituximab Leukemia Leukemia, Myelo… Leukemia, Myelo… Lymphoma Lymphoma, B-Cel… Acute Myelogeno… B-cell Lymphoma | The study was terminated by the Sponsor. - | |||
| NCT03728933 Details | 2023-10-26 Interventional | 3 | 23 | Rotigotine Psychomotor Agi… Restless Legs S… Syndrome | Sponsor decision; Not a safety decision - |